SCHEMBL25250119

SCHEMBL25250119

CN(C(=O)OC(C)(C)C)[C@H]1C[C@H](C(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.42
BTK Q06187 1/20 0.41
ASGR1 P07306 1/20 0.35
BUB1 O43683 1/20 0.33
HSD17B10 Q99714 1/20 0.33
APLNR P35414 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
KDM4D Q6B0I6 1/20 0.31
PIK3R1 P27986 1/20 0.31
PIK3CA P42336 1/20 0.31
USP30 Q70CQ3 1/20 0.30
MGLL Q99685 1/20 0.30
NFKB1 P19838 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25294971 1.00 HSD11B1 (0.42) HSD11B1BTKASGR1BUB1HSD17B10
SCHEMBL16513085 0.88 BTK (0.44) HSD11B1BTKASGR1BUB1HSD17B10
SCHEMBL181714 0.88 BTK (0.44) HSD11B1BTKASGR1BUB1HSD17B10
SCHEMBL2847124 0.88 BTK (0.44) HSD11B1BTKASGR1BUB1HSD17B10
SCHEMBL1663087 0.88 BTK (0.44) HSD11B1BTKASGR1BUB1HSD17B10
SCHEMBL27033054 0.87 BTK (0.54) HSD11B1BTKASGR1HSD17B10KMT2A
SCHEMBL23716710 0.87 BTK (0.54) HSD11B1BTKASGR1HSD17B10KMT2A
SCHEMBL30579727 0.86 HSD11B1 (0.42) HSD11B1BTKASGR1BUB1CHRM2
SCHEMBL24588156 0.84 HSD11B1 (0.41) HSD11B1BTKASGR1BUB1CHRM2
SCHEMBL1299111 0.84 HSD11B1 (0.41) HSD11B1BTKASGR1BUB1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240165243-A1 EGFR DEGRADERS AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2024-05-23 US disclosed
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 US disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE EGFR, CBL, ERBB2 HSD11B1 4449/4885BTK 809/4885ASGR1 787/4885
US-20240165243-A1 EGFR DEGRADERS AND METHODS OF USE EGFR, ERBB2, ERBB3 HSD11B1 4364/4885BTK 928/4885ASGR1 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.